Complex of synthetic 4-thiazolidinone derivatives with PEG-containing polymeric nanocarrier improve of biocompatibility and protects against toxicity in laboratory rats

The development of targeted drug delivery using conjugated nanoparticles brings more drug molecules to diseased sites, at the same time reducing the negative side effects of systemic drug exposure. In the present study, the binding capability of the newly developed biocompatible PEG-containing polymeric nanocarrier (PC) was demonstrated. The uptake and cytotoxicity of nanocarrier-immobilized anticancer drugs were enhanced compared to the free drugs. Approximately 10 times lower doses of the PC complexes achieved similar effects as the free form of the drug on cell cycle arrest, DNA damage, and apoptotic cell death (caspase 7 and PARP cleavage). We investigated anticancer effects of the compounds ID3882, ID3288 and ID3833, the drugs Doxorubicin (Dox) and PC complexes containing the compounds ID3882, ID3288 and ID3833 and Dox. PC complexes demonstrated reduced general toxicity, and enhanced anticancer effects in drug-sensitive and drug-resistant tumor cells, therefore improving the outcomes of oncotherapy.